CTOs on the Move

ICON Laboratories

www.iconlab.com

 
ICON Laboratories is a Farmingdale, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.iconlab.com
  • 123 Smith St
    Farmingdale, NY USA 11735
  • Phone: 631.306.5445

Executives

Name Title Contact Details

Similar Companies

Aquatic Biotechnologies Inc

Aquatic Biotechnologies Inc is a Camarillo, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Inscripta, Inc

Inscripta is a gene-editing technology company dedicated to creating the tools needed to revolutionize how we feed, fuel, and heal humanity.

Icagen

Icagen is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ImmunityBio

ImmunityBio is a vertically-integrated, clinical-stage biotechnology company developing next-generation therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. The company`s range of immunotherapy and cell therapy platforms, alone and together, act to drive and sustain an immune response with the goal of creating durable and safe protection against disease. We are applying our science and platforms to treating cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies that we believe sharply reduce or eliminate the need for standard high-dose chemotherapy. These platforms and their associated product candidates are designed to be more effective, accessible, and easily administered than current standards of care in oncology and infectious diseases.

Odonate

Odonate Therapeutics™ is dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Our initial focus is on the development of tesetaxel, an investigational, orally administered taxane. We are conducting our multinational, multicenter, randomized, Phase 3 study in locally advanced or metastatic breast cancer (MBC), known as CONTESSA. Our goal is to develop an effective chemotherapy choice for patients that provides quality-of-life advantages over current alternatives.